Literature DB >> 29955512

Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report.

P Brittany Vickery1, Lindsy Meadowcraft2, Stephen B Vickery3.   

Abstract

Neuroleptic malignant syndrome (NMS), which is considered a neurologic emergency, is believed to be caused by exposure to dopamine antagonist or withdrawal from a dopamine agonist. This article reports a case of suspected atypical NMS in a patient following rapid conversion of ziprasidone to risperidone without titration. While the initial presentation did not fully meet the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, diagnostic features, a sequential treatment strategy was initiated and the patient appropriately responded to antipsychotic cessation in addition to combination therapy with dantrolene and bromocriptine. Neuroleptic malignant syndrome diagnostic criteria, treatment, and prognosis are discussed.

Entities:  

Keywords:  NMS; antipsychotic; bromocriptine; catatonia; dantrolene; fluoxetine; neuroleptic malignant syndrome; risperidone; ziprasidone

Year:  2018        PMID: 29955512      PMCID: PMC6007570          DOI: 10.9740/mhc.2017.05.137

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  27 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

Review 2.  Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.

Authors:  M M Woodbury; M A Woodbury
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-11       Impact factor: 8.829

3.  An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.

Authors:  Ronald J Gurrera; Stanley N Caroff; Abigail Cohen; Brendan T Carroll; Francis DeRoos; Andrew Francis; Steven Frucht; Sanjay Gupta; James L Levenson; Ahsan Mahmood; Stephan C Mann; Michael A Policastro; Patricia I Rosebush; Henry Rosenberg; Perminder S Sachdev; Julian N Trollor; Varadaraj R Velamoor; Charles B Watson; Jayne R Wilkinson
Journal:  J Clin Psychiatry       Date:  2011-06-28       Impact factor: 4.384

4.  Risk factors for neuroleptic malignant syndrome. A case-control study.

Authors:  P E Keck; H G Pope; B M Cohen; S L McElroy; A A Nierenberg
Journal:  Arch Gen Psychiatry       Date:  1989-10

5.  Diagnostic uncertainty in a case of neuroleptic malignant syndrome.

Authors:  Dallas P Seitz
Journal:  CJEM       Date:  2005-07       Impact factor: 2.410

Review 6.  Mortality from neuroleptic malignant syndrome.

Authors:  A Shalev; H Hermesh; H Munitz
Journal:  J Clin Psychiatry       Date:  1989-01       Impact factor: 4.384

Review 7.  The neuroleptic malignant and serotonin syndromes.

Authors:  J R Carbone
Journal:  Emerg Med Clin North Am       Date:  2000-05       Impact factor: 2.264

8.  Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.

Authors:  Edoardo Spina; Angela Avenoso; Maria Gabriella Scordo; Maria Ancione; Aldo Madia; Giuliana Gatti; Emilio Perucca
Journal:  J Clin Psychopharmacol       Date:  2002-08       Impact factor: 3.153

9.  Atypical neuroleptic malignant syndrome.

Authors:  Ann Collins; Drew Davies; Sharmila Menon
Journal:  BMJ Case Rep       Date:  2016-06-13

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.